| Characteristics | 1) Cohort | 2) Cohort | ||||
| Entire n = 54 | LVEDP > 15 n = 28 | LVEDP ≤ 15 n = 26 | p-Value LVEDP > 15 vs < 15 | Entire n = 64 | AS only n = 43 | |
| Age, y | 66 ± 11.6 | 67 ± 11.8 | 64 ± 11.3 | 0.163 | 63 ± 13.8 | 67 ± 10.7 |
| Men, n (%) | 34 (63) | 16 (57) | 18 (69) | 0.408 | 43 (68) | 28 (65) |
| BMI | 26 ± 3.2 | 26 ± 3.3 | 27 ± 3 | 1 | 27 ± 3.4 | 28 ± 3.5 |
| EDD/BSA (mm/m2) | 28.3 ± 4.4 | 29 ± 4.9 | 28 ± 3.9 | 0.451 | 28 ± 4.1 | 26 ± 3.5 |
| ESD/BSA (mm/m2) | 16.1 ± 4.4 | 16 ± 4.9 | 16 ± 3.9 | 0.844 | 15.1 ± 4.1 | 14 ± 3.5 |
| E (cm/sec) | 99 ± 28 | 97 ± 29.6 | 101 ± 26.6 | 0.553 | 101 ± 30.5 | 103 ± 29 |
| E/A | 1.14 ± 0.45 | 1.1 ± 0.4 | 1.2 ± 0.5 | 0.654 | 1.16 ± 0.54 | 1.12 ± 0.59 |
| E-Deceleration time (msec) | 245 ± 75 | 247 ± 79.5 | 242 ± 71.7 | 0.812 | 230 ± 66 | 241 ± 70.4 |
| Main diseases |
|
|
|
|
|
|
| Aortic stenosis, n (%) | 33 (61) | 17 (61) | 16 (62) | 1 | 43 (67) | / |
| Regurgitation vitium, n (%) | 18 (33) | 11 (39) | 7 (27) | 0.396 | 21 (33) | / |
| Concomittant Diseases |
|
|
|
|
|
|
| Hyperlipidemia, n (%) | 13 (24) | 5 (18) | 8 (31) | 0.346 | 27 (42) | 21 (49) |
| Hypertension, n (%) | 26 (48) | 17 (61) | 9 (35) | 0.064 | 34 (53) | 26 (61) |
| Diabetes mellitus, n (%) | 8 (15) | 5 (18) | 3 (12) | 0.706 | 9 (14) | 7 (16) |
| Coronary Artery Disease, n (%) | 17 (32) | 8 (29) | 9 (35) | 0.771 | 11 (17) | 9 (21) |
| COPD, n (%) | 6 (11) | 4 (14) | 2 (8) | 0.670 | 3 (5) | 2 (5) |
| Drug Therapy |
|
|
|
|
|
|
| ACEI/ARB, n (%) | 42 (78) | 23 (82) | 19 (73) | 0.521 | 50 (78) | 31 (72) |
| ß-Blockers, n (%) | 29 (54) | 16 (57) | 13 (50) | 0.785 | 28 (44) | 17 (40) |